Results 51 to 60 of about 2,105 (152)

Deep early tumour shrinkage in metastatic upper tract urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab

BJU International, EarlyView.
Marie Semmler, Maurice Heimer, Can Aydogdu, Benazir Enzinger, Isabel Brinkmann, Frederik Kolligs, Gerald B. Schulz, Christian G. Stief, Philipp M. Kazmierczak, Jozefina Casuscelli, Lennert Eismann   +10 more
wiley   +1 more source

Early Recognition of Immune‐Related Hepatitis During Avelumab Maintenance Therapy for Urothelial Carcinoma

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Avelumab is recommended as maintenance therapy for advanced urothelial carcinoma after platinum chemotherapy; however, immune‐related adverse events can be severe and refractory. Case Presentation A 79‐year‐old male developed immune‐related hepatitis during avelumab maintenance therapy following gemcitabine plus carboplatin for ...
Yuka Iwama, Tomoyasu Sano, Yuta Sano, Tomokazu Kimura, Yushi Naito, Satoshi Inoue, Kazuna Matsuo, Shohei Ishida, Yoshihisa Matsukawa, Shusuke Akamatsu   +9 more
wiley   +1 more source

Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy

Biologics
Objectives: The aim of this study was to assess the association of diabetes mellitus and its medications with overall response (ORR) and mortality or cancer-specific survival (CSS) in patients with metastatic urothelial cancer receiving enfortumab ...
Laila Schneidewind, Bernhard Kiss, Friedemann Zengerling, Annemarie Uhlig, Niklas Klümper, Thomas Büttner, Julia Heinzelbecker, Thomas Elegeert, Cem Aksoy, Cindy Rönnau, Thilo Schiller, Oliver Hahn, Oliver Hakenberg, Georgios Gakis, Marco Hoffmann, Matthias Saar, Jennifer Kranz   +16 more
doaj   +1 more source

Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Bladder cancer (BC) is rarely associated with common bile duct (CBD) obstruction. We report a case of BC with peritoneal invasion and rectal involvement complicated by bilateral ureteral and biliary obstruction. Case Presentation A 77‐year‐old man presented with abdominal pain.
Kazuto Imai, Norihiko Masuda, Tatsuya Hazama, Toshihide Hosomi, Keita Hanada, Takakazu Matsushita, Toshiya Akao   +6 more
wiley   +1 more source

Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs

Frontiers in Oncology
ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 ...
Daiki Ikarashi, Tatsuya Kawamura, Keita Ogasawara, Yumeka Arakawa, Arisa Machida, Ayato Ito, Ei Shiomi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Jun Sugimura, Wataru Obara   +11 more
doaj   +1 more source

Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Avelumab maintenance after response to platinum chemotherapy improves outcomes in metastatic urothelial carcinoma. Progression during maintenance presents a therapeutic dilemma. Case Presentation A 72‐year‐old man underwent radical cystectomy and left nephroureterectomy for high‐grade urothelial carcinoma.
Fumihiro Ito, Koki Kobayashi, Gaku Hayashi, Shunsuke Kamijo, Takashi Fujita   +4 more
wiley   +1 more source

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
Background: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events.
Linlin Tang, Cuicui Sun, Wenshan Liu, Haiyan Wu, Chuanhua Ding   +4 more
doaj   +1 more source

Enfortumab Vedotin (Padcev)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Padcev should be reimbursed by public drug plans for the treatment of advanced or metastatic urothelial cancer (UC) if certain conditions are met. Padcev should only be covered to treat adult patients with UC who have already received treatment with a platinum-containing chemotherapy regimen, and a programmed death ...
openaire   +2 more sources

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis

Pharmaceuticals
Background/Objectives: Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that combines monomethyl auristatin E (MMAE), a potent cytotoxic agent, with a monoclonal antibody targeting Nectin-4. It has emerged as a promising therapy for metastatic
Grégoire Desimpel, François Zammit, Sarah Lejeune, Guillaume Grisay, Emmanuel Seront   +4 more
doaj   +1 more source

Therapeutic prospects of nectin-4 in cancer: applications and value

Frontiers in Oncology
Nectin-4 is a Ca2+-independent immunoglobulin-like protein that exhibits significantly elevated expression in malignant tumors while maintaining extremely low levels in healthy adult tissues.
Kaiyue Li, Yujing Zhou, Maolin Zang, Xin Jin, Xin Li   +4 more
doaj   +1 more source